us Thanks, Kyle. Hello, today. everyone, joining for thanks and
business. had a that strategic margin Lima we productive acquisition announced, solid the Recon expansion, continued changes previously we announced gain, our step quarter we As very third with and share of
quarter, X% XX% by about P&R. organic X brings growth X% our to growth these in Let's in highlights. We and and Slide grew X%. talk go growth year-to-date That in Recon, organically with the to
with growth in volumes with We third and which with gain normal we pandemic-related summer from likely double-digit surgery demand to was We XXXX down. XXXX worked volatility in elective versus in healthy strong side than a higher gradually believe a share the remain trend serve our procedural continued are procedure expectations. saw some a normal quarter persist the QX XXXX and of seasonality as compare. line expect will on Recon backlogs patient trend through markets return our We more we vacations, overall,
In mix P&R, we of bit quarter, a our points, recent in margin these of a margins scaling with acquisitions. basis XX showing gross had stable EBITDA share and gain another We the environment. leadership reestablished reflecting strong market our strong from productivity, markets adjusted by expansion expanded in
a about reach In exposure to definitive billion LimaCorporate, which September, that we announced the expands market. agreement $X segment taking Recon, to close with to global sales, to extremities in acquire XX% faster-growing in our
with momentum great track Overall, a we strong our remain goals. on strategic XXXX for versus
little deeper tough 'XX. on in organic Digging and X. led in hip a U.S., year XX% a We against double-digit knee. by XX% QX Slide growth grew X% had Recon Extremities of the of growth comp prior in in
about the excited Outside growth good expand market with I'm products. XX% our international and our resilient AltiVate for position we the traction almost as in grew a opportunity industry-leading organically U.S., EMPOWR market. we initial
Knee The to have pipeline allow a and launched updated take we ramp will innings, of come. early with ARVIS we EMPOWR in years in capability. X.X continue Recon many believe innovation to our remains strong for also of Importantly, have full that us share Revision the we to an EMPOWR
these feedback products. all recently Lapidus the launched the great we for X on from We've one the new in EvolveXX and Correction foot of of System U.S. bunions, in fastest-growing terrific market ankle, Additionally, segments had surgeons
I acquisition have to Lima of take about Lima. and the with Turning was the activities, the in and the exciting planning big leaders we I to with remind making have our ahead. opportunity came to that our moment on and the to and We're want we a recently Mathys headway integration good and with teams. increased away Slide of X. opportunity talent Switzerland, everyone business by Italy I meeting conviction strength and the advance excitement
gets acquisitions have start We and financial contributions a shareholder to track record returns. experience sure of lot a our this great and playbook strategic make strong impact, deliver proven and doing are following well, EGX to and one off
represents sustained the for our goal Enovis of Lima we The a expansion. evolution addition clear innovator the to with as strategic execute in med operating a tech next margin against of build pathway step high-growth
close transaction, fastest-growing growth, expected the extremities. our parts and reshape higher-margin expansion scale. continuous is our progress our market Recon of against recon pillars organic global accelerates single-digit faster-growing, to mix This This our increased strategic of to exposure the long-term margin to will which sustainable in XXXX, early high and and
is a business strong P&R This with in over X% healthy strategic service, improving is disciplined environment with from year-to-date Global our growth In gains execution. market and share Slide our innovation conversions. and reflects on clinic organic bracing performing X% plan. customer line growth X, MotionMD
electrotherapy strong of growth, Sciences team. to ROAM, products for innovation a drive called pipeline brace including and the generation additional knee next OA of our have a We new clinical Recovery
EGX driving this as versus in and sustain traction on we segment cost tools, XXX productivity system price notable expanded additional out roll points which improvements. margins continue business basis by Gross to are
Slide X. to Moving
to confidence over year-to-date. it in to team's want the I hand reiterate execution Ben, our I Before
our day-to-day the world global we lot diverse been a execution has deliver takes have. a And thankfully from XXXX bit while recent consistently the than way around to have We members normal a more it team business. of years,
high-single-digit comes commitment capability to value growth low- compounding The to our double and to create mid-single-digit along shareholder with grow high-single-digit in shows organic execution stable continuous consistently growth. Our expansion. through from and ability margin demonstrated XXXX our P&R our digits, Recon growth
investments grow headwinds. as Recon margin faster, offset scale, supplemented margin EGX the expansion by comes in-year we structural from by and productivity The expansion and growth gross partially
provide continue compounding this for update up a recent guidance will growth are formula impact our quarter in fourth XXXX margin call, drive ramp more we our but to the on formal and ability acquisitions. of also confident in We to
Now I'll guidance the you let the P&L details and Ben? increase. through Ben take